Across TCGA pan-cancer cohorts, MICB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MICB data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MICB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MICB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where MICB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.090	0.688	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.630	.025	14	view →
SKCM	DFS	Median	IV	0.028	0.477	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MICB tumor-vs-normal RNA expression · all MICB data types